

ARK Genomic Revolution ETF

ARKG | Cboe BZX Exchange, Inc.



ANNUAL SHAREHOLDER REPORT | JULY 31, 2025

This annual shareholder report contains important information about ARK Genomic Revolution ETF (the "Fund") for the period of August 1, 2024 to July 31, 2025. You can find additional information about the Fund at <https://www.ark-funds.com/download-fund-materials/>. You can also request this information by contacting us at (727) 810-8160.

What were the Fund’s cost for the period?

(based on a hypothetical \$10,000 investment)

Fund	Costs of a \$10,000 investment	Costs paid as a percentage of a \$10,000 investment
ARK Genomic Revolution ETF	\$71	0.75%

Management’s Discussion of Fund Performance

SUMMARY OF RESULTS

The Fund underperformed both the S&P 500 Index and the MSCI World Index for the 12-month period ending July 31, 2025. The headwinds that once pressured disruptive technologies shifted into structural tailwinds, supported by broadening market participation, favorable policy shifts around crypto, AI, and healthcare, and potential fiscal catalysts like tax cuts. Still, many companies in the genomics space remain under pressure as they prioritize long-term growth over near-term profitability.

ARK’s research suggests that a rolling recession began in the spring of 2022, when the Federal Reserve raised interest rates 22-fold in just over a year. We believe that waning pricing power is likely to force corporations into further employment cutbacks to preserve margins. Innovation often takes root in turbulent times: when consumers and businesses confront uncertainty, they are more willing to adopt better, faster, and less costly solutions.

Top contributors to relative performance


- The top contributor to performance during the period was Adaptive Biotechnologies Corp. (ADPT). Shares of ADPT rose during the period after strong performance in its 1Q25 earnings, marked by a 34% growth in MRD (Minimal Residual Disease) revenue, driven by an uptick in clonoSEQ test volume. The company raised its full-year MRD revenue guidance, highlighting the scalability and momentum in its MRD business, while also reducing its operating expenses and cash burn targets.
- Additional contributors to performance included Tempus AI, Inc., Guardant Health, Inc., Personalis, Inc., and Accolade, Inc.

Biggest detractors from relative performance

- The biggest detractor from performance during the period was Twist Bioscience Corp. (TWST). Shares of TWST detracted from the Fund performance following the NIH’s announcement to cut indirect costs on grants, which is expected to significantly impact research funding and spending behavior among researchers.
- Additional detractors from performance included Intellia Therapeutics, Inc., Beam Therapeutics, Inc., Recursion Pharmaceuticals, Inc., and Arcturus Therapeutics Holdings, Inc.

Fund Performance

Growth of an Assumed \$10,000 Investment



AVERAGE ANNUAL TOTAL RETURNS	1 Year	5 years	10 Years
ARK Genomic Revolution ETF - NAV	-11.46%	-14.72%	1.30%
Nasdaq Healthcare Index	-6.94%	-1.29%	1.48%
MSCI World Index (Net)	15.72%	13.78%	10.60%
S&P 500 Index	16.33%	15.88%	13.66%

Past performance does not guarantee future results. The performance data quoted represents past performance and current returns may be lower or higher. The investment return and principal value will fluctuate so that an investor's shares, when redeemed, may be worth more or less than the original cost. To obtain performance information current to the most recent month end, please visit www.arkfunds.com. Additional information about fees and expense levels can be found in the ARK ETFs' current prospectuses. Net asset value ("NAV") returns are based on the dollar value of a single share of an ARK ETF, calculated using the value of the underlying assets of the ARK ETF minus its liabilities, divided by the number of shares outstanding. The NAV is typically calculated at 4:00 pm Eastern time on each business day the New York Stock Exchange is open for trading.

The returns for the Fund do not reflect the deduction of taxes that a shareholder would pay on Fund distributions or upon sale of Fund shares.

Fund Statistics

The following table outlines key Fund statistics that you should pay attention to:

Fund net assets	\$1,011,802,935
Total number of portfolio holdings	35
Total advisory fees paid	\$8,564,967
Period portfolio turnover rate	33%

Graphical Representation of Holdings

The table below shows the investment makeup of the Fund. The allocations may not be representative of the Fund's future investments.

Sector Diversification	% of Total Investments
Health Care	98.5%
Information Technology	1.4%
Financials (Money Market Fund)	0.1%
Total	100.0%

Availability of Additional Information

If you wish to find additional information about the Fund such as the prospectus, financial information, fund holdings and proxy voting information, please see the website address <https://www.ark-funds.com/download-fund-materials/> or contact number (727) 810-8160 included at the beginning of this shareholder report.